Company Profile
Translate Bio
Company Overview
Translate Bio is a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company’s RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases caused by insufficient protein production, including rare diseases of the liver, lung and central nervous system (CNS). For more information about the company, please visit www.translate.bio.
Notable Accomplishments / Recognition
In January 2017, Translate Bio announced the company acquired the MRT platform – a messenger RNA (mRNA) therapy platform developed by subsidiaries of Shire plc – significantly expanding the company’s ability to potentially correct a wide range of disease genotypes regardless of mutation and access new targets not currently addressable by existing modalities. Resulting from the acquisition, the company also welcomed Shire’s former MRT employees and gained two near-clinic programs in cystic fibrosis and ornithine transcarbamylase (OTC) deficiency, a urea cycle disorder.